The two-step approach to allogeneic hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Immunology
• Transplantation Science

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for hematological diseases.
• Achieving optimal outcomes requires balancing immune recovery, graft-versus-host disease (GVHD), and disease control.
• Traditional HSCT methods face challenges in optimizing this balance.

Purpose of the Study:

• To describe the two-step HSCT platform developed at Thomas Jefferson University.
• To review key results and lessons learned from two decades of using this approach.
• To discuss strategies for enhancing graft-versus-tumor effects and minimizing transplant toxicity.

Main Methods:

• A two-step HSCT protocol involving donor CD3+ cells (day -6) followed by cyclophosphamide (CY) (days -3, -2).
• Infusion of CD34-selected stem cells on day 0 after CY administration.
• This method separates lymphoid and myeloid grafts and avoids exposing stem cells to alkylating agents.

Main Results:

• The two-step approach aims to optimize T-cell dosing and induce donor-recipient tolerance.
• Stem cell infusion after CY tolerization allows for rapid count recovery.
• The platform has been refined over two decades to improve outcomes.

Conclusions:

• The two-step HSCT platform offers a strategy to balance critical aspects of transplantation.
• Continuous refinement focuses on maximizing anti-leukemic effects while reducing toxicity.
• This approach represents a significant advancement in allogeneic HSCT for hematological conditions.